**4. Prospect**

Clinically, the high incidence and mortality rate of complex diseases like tumors cry for the new early-diagnosis patterns and effective early-diagnosis markers. In the mining of the mass spectrometric data, the cluster analysis and classification analysis have been used, but many problems still need further studies. In particular, the pretreatment of MS profiling, there is no standard method available. These issues are critical for putting serum peptidome into clinical detection. Secondly, along with the instant development and application of

Serum Peptidomics 391

[12] Paradis V, Degos F, Dargère D, Pham N, Belghiti J, Degott C, Janeau JL, Bezeaud A,

[13] Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB,

[14] Taku N, Sharon KH , Steve RM, et al. Proteomic profiling of primary breast cancer

[15] van Winden AW, Gast MC, Beijnen JH, Rutgers EJ, Grobbee DE, Peeters PH, van Gils

[16] Villanueva J, Philip J, Chaparro CA, Li Y, Toledo-Crow R, DeNoyer L, Fleisher M,

[17] Wasinger VC, Cordwell S J, Cerpa PA, et al. Progress with gene product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis, 1995, 16 (7): 1090-1094. [18] Wei YS, Zheng YH, Zhang ZH, et al. Identification of serum biomarkers for nasopharyngea carcinoma by proteomic analysis. *Cancer*, 2008, 12 ( 3): 544-551. [19] Yoshizaki T, Enomoto T, Nakashima R, e t al. Altered protein expression in endometrial

[20] Zhang R, Barker L, Pinchev D, et al. Mining biomarkers in human sera using proteomic

[21] Johnson, KL, Mason, CJ, Muddiman, DC, etal. Analysis of the low molecular weight

Precision of time, mass, and ion abundance. Anal Chem, 2004, 76:5097-5103. [22] Soltys SG, Le QT, Shi G, etal. The Use of plasma Surface-Enhanced Laser

[23] Honda K, Hayashida Y, Umaki T, et al.Possible detection of pancreatic cancer by

[24] Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activity confer tumor-

[26] Cheng AJ, Chen LC, Chien KY, et al. Oral Cancer Plasma Tumor Marker identified with

[27] YIP T TC, Chan J WM, Cho W CS, et al. Protein chip array profiling analysis in patients

Bead-Based Affinity Fractionated Proteomic Technology. Clin Chem, 2005, 51:2236-

with severe acute respiratory syndrome identified serum amyloid: a protein as a a biomarker potentially useful in monitoring the extent of pneumonia. Clin Chem,

specific serum Peptidome Patterns. J Clin Invest, 2006, 116:271-284.

plasma protein profiling. Cancer Res, 2005, 65:10613-10622.

[25] Novak K. Biomarkers:Taking out the Trash. Nature, 2006, 6:92.

fraetion of serum by LC-Dual ESI-FT-ICR mass speetrometry:spectrometry:

Desorption/ionization Time-of-Flight Mass Spectrometry proteome patterns for detection of head and neck squamous cell cancers, Clinical Cancer Research, 2004,

SELDI-TOF MS: a case control study. *BMC Med Genomics*,2009,2:4.

serum peptide signatures. *J Proteome Res*,2005, 4(4):1060-1072.

carcinogenesis. *Cancer Lett*, 2005, 226 (2):1012 - 1061.

tools. *Proteomics*, 2004, 4(1): 244-256.

10:4806-812.

2244.

2005, 51(l):47-55.

identify ovarian cancer. *Lancet*, 2002, 359(9306):572-577.

2003, 49: 752-760.

8 3 0.

Delforge D, Poon TC, Yip TT, Chan AT, Yip C, Yip V, Mok TS, Lee CC, Leung TW, Ho SK, Johnson PJ. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. *Clin Chem,* 

Simone C, Fishman DA, Kohn EC et al: Use of proteomic patterns in serum to

predicts axillary lymph node metastasis. *Cancer Res*, 2 0 0 6, 6 6 ( 2 4 ) : 1 1 82 5 - 1 1

CH. Validation of previously identified serum biomarkers for breast cancer with

Robbins RJ, Tempst P. Correcting common errors in identifying cancer-specific

mass spectrometer and serum peptidome technology, a lot of serum polypeptide profiling data have been produced. It has become an international competition focus in the postgenome era how to develop an effective bioinformatics instrument to determine proteins related to some vital phenomena (like growth, upgrowth, tumor onset) from the substantive data including peptide mass and intensity and their functions. It is believed that with the progressive development and application of serum peptidomics technology and the ClinTOF system, better clinical models will appear and more early-stage tumor biomarkers will be discovered and identified. Also, great breakthroughs will be made in the pathogeny, diagnosis and treatment of complex diseases, to cultivate new hope for research, diagnosis and treatment of many diseases.

#### **5. References**


mass spectrometer and serum peptidome technology, a lot of serum polypeptide profiling data have been produced. It has become an international competition focus in the postgenome era how to develop an effective bioinformatics instrument to determine proteins related to some vital phenomena (like growth, upgrowth, tumor onset) from the substantive data including peptide mass and intensity and their functions. It is believed that with the progressive development and application of serum peptidomics technology and the ClinTOF system, better clinical models will appear and more early-stage tumor biomarkers will be discovered and identified. Also, great breakthroughs will be made in the pathogeny, diagnosis and treatment of complex diseases, to cultivate new hope for research, diagnosis

[1] Andrew Tarnaris, Laurence D Watkins and Neil D Kitchen. Biomarkers in chronic adult

[2] Brichory F, Beer D, Le Naour F, et al. Proteomics- based identification of protein gene

[3] Cho WC, Yip TT, Yi PC, et al. Identification of serum amyloid a protein as a potentially

[4] Cruz-Marcelo A, Guerra R, Vannucci M, et al. Comparison of algorithms for pre-

[5] Cubizolles M, Laurendeau I, Bedossa P. Identification of a new marker of hepatocellular

[6] Doustjalali SR, Yuso f R, Gov indasamy GK, et al. Patients with nasopharyngea

[7] Gast M C, van Du lken E J, van Loenen TK, et al. Detection of breast cancer by surface

[8] Guo X, Cao SM, Y u JK, et al. Distinct seruma proteomic patterns between ascending and

[9] Huang Y J, Xuan C, Zhang BB, e t al. SELDI-TOF-MS profiling of serum for detection of

[10] Hye A , Lynham S, Thambisetty M , et al. Proteome based plasma biomarkers for

[11] Liao QL, Zhao L, Chen X, et al. Serum proteome analysis for profiling protein markers

carcinoma. *Clinical and Experimental Metastasis*, 2008, 25( 4): 465-476.

serum protein profiling. *Int J BioMarkers*, 2009, 24 (3): 130 -141.

nasopharyngea carcinoma.*Cancer*, 2008 , 112( 3): 544-551.

Alzheimer 's disease. *Brain* , 2006,129 (Pt11): 3042-3050.

product as a tumor antigen that induces a humoral immune response in lung

useful biomarker to monitor relapse of nasopharyng eal cancer by serum proteomic

processing of SELDI-TOF mass spectrometry data. *Bioinformatics*, 2008, 24:2129-

carcinoma by serum protein profiling of patients with chronic liver diseases.

carcinoma demonstrate enhanced serum and tissue cerulo plasm in expression. *J* 

enhanced laser desorption/ionization time of flight mass spectrometry tissue and

descending types of locoregionally advanced nasopharyng eal carcinoma assessed by surface enhanced laser desorption ionization and analyses. *Chin Med J*, 2005,

associated with carcinogenesis and lymph nodemetastasis in nasopharyngea l

hydroce-phalus. Cerebrospinal Fluid Research, 2006,3:11.

cancer. *Cancer Res*, 2001, 61(21) : 7908- 7912.

profiling. *Clin Cancer Res*, 2004, 10: 43-52.

*Hepatology,* 2005; 41: 40-47.

*Med Invest*, 2006, 53: 20-28.

118( 22): 1912-1917.

and treatment of many diseases.

**5. References** 

2136.


[28] Semmes OJ, Feng Z, Adam BL, et al. Evaluation of serum protein profiling by surface-

[29] Dekker LJ, Boogerd W, Stockhammer G, Et al. MALDI-TOF mass spectrometry analysis

[31] Dobrin N, Urban A.K, Erie E.N., et al. Population Proteomics. Mol Cell Proteomics 2006,

[32] Agranoff D, Delmiro FR, Papadopoulos MC, et al.. Identification of diagnostic markers

[33] Emanuel FP, Claudio B, Robyn P, et al. The blood peptidome: a higher dimension of

age. Mol Cell Proteomic, 2006, 5(10):1840-1852.

2005, 51:102-12.

5(10):1811-1818

1021

967

enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of Prostate cancer: assessment of platform reproducibility. Clin Chem,,

of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancerMol Cell Proteomics, 2005, 4:1341-1349. [30] Villanueva J, Martorella AJ, Lawlor K, et al. Serum peptidome patterns that distinguish

metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and

for tuberculosis by proteomic fingerprinting of serum. Lancet, 2006,368(9540):1012-

information content for cancer biomarker discoverNat Rev Cancer,2006,6(12):961-
